Medicare Pilot Program for Weight-Loss Drugs Indefinitely Delayed, Impacting Eli Lilly's Market Access
LLY sits 46% above its 52-week low of $623.78.
Summary
The Trump Administration has indefinitely delayed a Medicare pilot program designed to cover weight-loss drugs. This development is a significant negative for Eli Lilly, which has recently launched its new oral obesity pill, Foundayo, and continues to see robust demand for its existing GLP-1 drugs like Mounjaro and Zepbound, as highlighted by recent strong earnings and positive trial results. The delay directly impacts the addressable market for LLY's key growth drivers, limiting access to a large patient population and deferring a potentially substantial revenue stream. While UnitedHealth Group (UNH) would also be affected as a Medicare Advantage provider, the direct impact on Eli Lilly's product sales and growth trajectory is more pronounced. Traders will closely monitor any further policy updates regarding Medicare coverage for these drugs and potential adjustments to LLY's sales forecasts.
At the time of this announcement, LLY was trading at $907.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $853.2B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.